ng-nitroarginine methyl ester has been researched along with Carcinoma, Anaplastic in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katiyar, SK; Punathil, T; Tollefsbol, TO | 1 |
| Giliano, NY; Konevega, LV; Noskin, LA | 1 |
| Badn, W; Kalliomäki, S; Sjögren, HO; Widegren, B | 1 |
3 other study(ies) available for ng-nitroarginine methyl ester and Carcinoma, Anaplastic
| Article | Year |
|---|---|
EGCG inhibits mammary cancer cell migration through inhibition of nitric oxide synthase and guanylate cyclase.
Topics: Animals; Anticarcinogenic Agents; Carcinoma; Catechin; Cell Line, Tumor; Cell Movement; Cyclic GMP; Enzyme Inhibitors; Guanylate Cyclase; Mammary Neoplasms, Animal; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Nitrogen Oxides; Oxadiazoles; Quinoxalines | 2008 |
Dynamics of intracellular superoxide and NO content in human endotheliocytes and carcinoma cells after treatment with NO synthase inhibitors.
Topics: Carcinoma; Cell Line, Tumor; Dicarbethoxydihydrocollidine; Endothelial Cells; Fluorescence; Guanidines; Humans; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; Superoxides | 2010 |
Low-dose combretastatin A4 phosphate enhances the immune response of tumor hosts to experimental colon carcinoma.
Topics: Administration, Oral; Animals; Carcinoma; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Dose-Response Relationship, Immunologic; Humans; Injections, Intraperitoneal; Interferon-gamma; NG-Nitroarginine Methyl Ester; Nitric Oxide; Rats; Rats, Inbred BN; Rats, Inbred WF; Stilbenes; Structure-Activity Relationship; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2006 |